Abstract
Influenza A virus poses a direct threat to humans and results in the deaths of about 36,000 people each year in USA. There is tremendous concern that highly virulent variants of the virus may emerge and cause a major pandemic. The influenza virus attacks the respiratory tracts and may cause acute lung inflammation. Certain evidence suggests that the lethal effect of the influenza virus results from inflammation of the host lung rather than from direct viral cytopathy. This has led to the concept that co-administration of effective antiviral agents with inflammation attenuators, by which a reduction, but not an elimination of inflammation would improve lung function without compromising virus clearance, and might result in a better treatment outcome of virulent influenza. Anti-inflammatory antibodies are widely developed for treatment of inflammatory diseases such as Crohns disease, ulcerative colitis, rheumatoid arthritis, psoriasis and so on. This review focuses on anti-inflammatory antibodies and discusses the feasibility and prospects for using them to attenuate the host inflammatory responses in the lung for the treatment and disease management of virulent influenza.
Keywords: Anti-inflammatory antibodies, inflammation attenuators, influenza A virus, treatment and disease management of virulent influenza
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Feasibility and Prospects for Anti-Inflammatory Antibodies in the Treatment and Disease Management of Influenza
Volume: 7 Issue: 2
Author(s): Wei-Gang Hu and Jonathan P. Wong
Affiliation:
Keywords: Anti-inflammatory antibodies, inflammation attenuators, influenza A virus, treatment and disease management of virulent influenza
Abstract: Influenza A virus poses a direct threat to humans and results in the deaths of about 36,000 people each year in USA. There is tremendous concern that highly virulent variants of the virus may emerge and cause a major pandemic. The influenza virus attacks the respiratory tracts and may cause acute lung inflammation. Certain evidence suggests that the lethal effect of the influenza virus results from inflammation of the host lung rather than from direct viral cytopathy. This has led to the concept that co-administration of effective antiviral agents with inflammation attenuators, by which a reduction, but not an elimination of inflammation would improve lung function without compromising virus clearance, and might result in a better treatment outcome of virulent influenza. Anti-inflammatory antibodies are widely developed for treatment of inflammatory diseases such as Crohns disease, ulcerative colitis, rheumatoid arthritis, psoriasis and so on. This review focuses on anti-inflammatory antibodies and discusses the feasibility and prospects for using them to attenuate the host inflammatory responses in the lung for the treatment and disease management of virulent influenza.
Export Options
About this article
Cite this article as:
Hu Wei-Gang and Wong P. Jonathan, Feasibility and Prospects for Anti-Inflammatory Antibodies in the Treatment and Disease Management of Influenza, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2008; 7 (2) . https://dx.doi.org/10.2174/187152308784533212
DOI https://dx.doi.org/10.2174/187152308784533212 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Implications of microRNAs in the Pathogenesis of Atherosclerosis and Prospects for Therapy
Current Drug Targets Novel Carriers for Controlled Site Specific Delivery of Anti-Inflammatory Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Clinical Applications of Non-Antimicrobial Actions of Tetracyclines in Inflammatory Diseases
Current Drug Therapy Molecules to Selectively Target Receptors for Treatment of Pain and Neurogenic Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Carbohydrate based Potential Chemotherapeutic Agents: Recent Developments and their Scope in Future Drug Discovery
Mini-Reviews in Medicinal Chemistry Formulation and Evaluation of Liposomal Drug Delivery System for Sulfasalazine
Current Nanomedicine Rabbit Models of Ocular Diseases: New Relevance for Classical Approaches
CNS & Neurological Disorders - Drug Targets The Initiation Mechanisms of Gene Expression in Ascitic Hepatoma Cells Under the Action of Dehydroepiandrosterone in a Complex with Apolipoprotein A-I
Current Chemical Biology Bronchoalveolar Lavage in Systemic Sclerosis Patients: A Systematic Review
Current Rheumatology Reviews Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Current Drug Targets Functional Characteristic of Snake Venom Disintegrins: Potential Therapeutic Implication
Current Pharmaceutical Design Regulation of Inflammatory Responses by Oxidized Phospholipids: Structure-Function Relationships
Current Pharmaceutical Design Total Phenolic Content and In vitro Antioxidant Activity of Endophytic Fungi Isolated from Calotropis procera L.
Current Bioactive Compounds Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design MMP Inhibitors in Cardiac Diseases: An Update
Recent Patents on Cardiovascular Drug Discovery Recent Developments in Patent Anti-Cancer Agents Targeting the Matrix Metalloproteinases (MMPs)
Recent Patents on Anti-Cancer Drug Discovery Targeting Lipoxygenases (LOs): Drug Design And Discovery
Current Enzyme Inhibition Targeting Leukocytes in Immune Glomerular Diseases
Current Medicinal Chemistry Rheumatoid Arthritis: Seropositivity versus Seronegativity; A Comparative Cross-sectional Study Arising from Moroccan Context
Current Rheumatology Reviews